SeekingAlpha · Aug 29, 2026
Abrdn Life Sciences Investors Q2 2026 Commentary
abrdn Life Sciences Investors (HQL) outperformed its benchmark as uniQure and Personalis posted strong gains. Read the full report for detailed performance data.
HQ
NYSE · HQL
Tekla Life Sciences Investors
Financial Services · Asset Management
$19.86
Up+$0.10 (+0.51%)
Updated Sep 15, 2026, 8:30 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 497.33M
- P/E ratio
- -40.78
- Dividend yield
- 9.16%
- 52-week range
- $15.82 – $22.67
- Volume
- 128.57K
- Avg. volume
- 194.28K
Price performance
HQL price history
1M range · 20 trading sessions · Daily adjusted prices
HQL closed at $19.86 after 20 trading sessions, down 7.07% for the selected period.
- Last close
- $19.86
- Period change
- -7.07%
- Period low
- $19.76
- Period high
- $22.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 14, 2026 | $19.76 | $19.8997 | $19.46 | $19.86 | 128.57K |
| Sep 11, 2026 | $19.86 | $19.96 | $19.59 | $19.76 | 134.32K |
| Sep 10, 2026 | $20.34 | $20.34 | $19.68 | $19.79 | 151.08K |
| Sep 9, 2026 | $20.62 | $20.67 | $20.29 | $20.34 | 92.93K |
| Sep 8, 2026 | $20.53 | $20.63 | $20.30 | $20.56 | 121.34K |
| Sep 4, 2026 | $20.76 | $20.76 | $20.48 | $20.64 | 110.75K |
| Sep 3, 2026 | $21.17 | $21.17 | $20.4176 | $20.71 | 136.3K |
| Sep 2, 2026 | $20.96 | $21.43 | $20.72 | $20.98 | 141.24K |
| Sep 1, 2026 | $20.93 | $21.10 | $20.7624 | $20.87 | 108.39K |
| Aug 31, 2026 | $20.99 | $21.03 | $20.7201 | $20.92 | 155.25K |
| Aug 28, 2026 | $21.45 | $21.58 | $20.85 | $20.96 | 164.31K |
| Aug 27, 2026 | $21.57 | $21.6999 | $21.40 | $21.55 | 107.83K |
| Aug 26, 2026 | $21.66 | $21.80 | $21.3071 | $21.53 | 121.21K |
| Aug 25, 2026 | $21.76 | $21.83 | $21.5414 | $21.67 | 146.92K |
| Aug 24, 2026 | $21.78 | $21.78 | $21.26 | $21.55 | 94.73K |
| Aug 21, 2026 | $22.11 | $22.5109 | $22.11 | $22.38 | 171.37K |
| Aug 20, 2026 | $22.50 | $22.62 | $22.00 | $22.08 | 208.26K |
| Aug 19, 2026 | $21.93 | $22.67 | $21.93 | $22.67 | 292.46K |
| Aug 18, 2026 | $21.39 | $21.72 | $21.1907 | $21.72 | 172.09K |
| Aug 17, 2026 | $21.19 | $21.46 | $21.02 | $21.37 | 128.51K |
Latest HQL news
The latest Smart Investors Daily articles mentioning HQL.
Stock researchCompany · Overview
HQL research
Overview
Company profile and research snapshot.
Company profile
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 13, 2026
abrdn Life Sciences Investors Q2 2026 Commentary
The equity portion of the Fund rose (gross of fees) and outperformed its benchmark, the NASDAQ Biotechnology Index. Read more here.
SeekingAlpha · Feb 25, 2026
Abrdn Life Sciences Investors Fund Q4 2025 Commentary
Yahoo · Feb 10, 2026
Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on February 27, 2026 to all shareholders of record as of February 20, 2026 (ex-dividend date February 20, 2026). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), t
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
